Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding

@article{Cohen2014PayingTQ,
  title={Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding},
  author={Deborah Cohen and James Raftery},
  journal={BMJ : British Medical Journal},
  year={2014},
  volume={348}
}
Deborah Cohen and James Raftery ask why one of the first drugs to be developed by a partnership between a charity and a drug company also ended up being one of the world’s most expensive drugs. Why didn’t such philanthropy lead to greater patient access? 
Cystic Fibrosis Trust’s clarification of Cohen and Raftery’s article on cystic fibrosis drug development
  • E. Owen
  • Medicine
    BMJ : British Medical Journal
  • 2014
TLDR
Cohen and Raftery’s feature on the high cost of a cystic fibrosis drug developed with charitable funding used a novel approach called “informed consent” to estimate the cost-effectiveness of the drug.
Propaganda or the cost of innovation? Challenging the high price of new drugs
Concern is growing about the implications of rising drug prices for individuals and health systems around the world. With little transparency around the costs of drug development, Narcyz Ghinea and
A new model for drug development using a multi-stakeholder consortium
  • A. Hall
  • Medicine
    BMJ : British Medical Journal
  • 2014
TLDR
The difficulties of new collaborative drug development models are highlighted, and several charities now fund and collaborate in drug research and development can create ethical tension if donations from the public are used for commercial gain.
Cost(s) of caring for patients with cystic fibrosis
TLDR
This article reviews recent developments in CF science and treatment, and highlights areas that contribute to costs of CF care, emphasizing how these costs have increased.
Venture Philanthropy: A Case Study of the Cystic Fibrosis Foundation
TLDR
The Cystic Fibrosis (CF) Foundation is highlighted, widely considered to be the leading VP organization in biotech, which facilitated the development of Kalydeco, the first disease-modifying therapy approved to treat cystic fibrosis.
Expensive medicines: ensuring objective appraisal and equitable access
TLDR
It is argued that all involved in bringing medicines to market need to be explicit about the additional information required, decide how these data should be collected and assessed and the methods that should be used to set a fair price for a new drug.
Competing for public funding of medicines to treat rare disorders in New Zealand
  • Steffan Crausaz
  • Medicine, Political Science
    Bulletin of the World Health Organization
  • 2015
TLDR
New Zealand’s pharmaceutical management agency developed a set of prerequisites for medicines that would be eligible for consideration under the rare disorders funding process and issued a request for proposals, attracting many offers from companies seeking funding for medicines for rare disorders.
Controversies with Kalydeco: Newspaper coverage in Canada and the United States of the cystic fibrosis "wonder drug".
  • C. Rachul, M. Toews, T. Caulfield
  • Medicine, Political Science
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
  • 2016
Pricing of pharmaceuticals is becoming a major challenge for health systems
Manufacturers using their market power to maximise profits results in prices that are unjustifiable and unaffordable, argue Steven Morgan and colleagues
Findacure: empowering patient groups for drug development
TLDR
There is a large unmet need for helping rare disease patient groups and Findacure aims to empower these groups to become effective campaigners for change using multi-stakeholder collaborative models.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 20 REFERENCES
Pricing for orphan drugs: will the market bear what society cannot?
TLDR
The development program that led to the discovery of ivacaftor was firmly grounded and incrementally built on the many contributions made during at least 3 decades by a highly supportive community built by and around patients and their families affected by this disease.
Pricing of orphan drugs
Chance of life
Kalydeco-Vertex Pharmaceuticals
  • 2013
Uncertain harm-benefit balance
  • Prescrire Int
  • 2013
2 Food and Drug Administration. FDA approves Kalydeco to treat rare form of cystic fibrosis. Press release
  • JAMA
  • 2012
Centre for Drug Evaluation and Review. Summary review of regulatory action
  • 2012
Clinical commissioning policy: ivacaftor for cystic fibrosis
  • 2012
Driven by loss, father inspires tireless pursuit of a cure
  • 2012
NHS Commissioning Board
...
1
2
...